Table 1 Clinical characteristics of the patient population in this study
Patient | Age | Sex | Antibiotics Pre C. difficile infection | Antibiotics used to treat C. difficile infection | Resolution of C. difficile infection |
|---|---|---|---|---|---|
1 | 35 | F | Co-amoxiclavMetronidazole | Metronidazole, Vancomycin, Fidaxomicin | No |
3 | 35 | F | As above | As above | Yes |
2 | 24 | F | Erythromycin Azithromycin | Vancomycin, Fidaxomicin | Yes |
4 | 54 | F | Co-amoxiclav | Metronidazole, Vancomycin, Fidaxomicin | Yes |
5 | 69 | F | Tazobactam, Piperacillin Co-amoxiclav | Metronidazole Vancomycin Fidaxomicin | Yes |
6 | 65 | F | Flucoloxacillin Calvepen Benzylpenicillin Co-amoxiclav | Metronidazole, Vancomycin | Yes |
7 | 90 | F | Cefuroxime Cephalexin | Metronidazole Vancomycin Fidaxomicin | Yes |
8 | 58 | F | Tazobactam Piperacillin Vancomycin, Meropenem | Metronidazole Vancomycin Fidaxomicin | Yes |
10 | 22 | M | None | Vancomycin | Yes |
11 | 68 | M | Tazobactam Piperacillin | Metronidazole Vancomycin Fidaxomicin | Yes |